AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01524614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasal mask
Description: nasal mask use instead of face mask
Study NCT02209935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Rehabilitation Protocol
Study NCT02209935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT03369665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavenclad®
Description: Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
Study NCT02776046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High FiO2
Description: High FiO2 with a perioperative open lung strategy
Study NCT02776046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional FiO2
Description: Conventional FiO2 with a perioperative open lung strategy
Study NCT04669132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: - Olanzapine 5mg, administered once daily, during 5 days (day before chemotherapy, the D day of the chemotherapy and 3 day after chemotherapy)
Study NCT04669132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant
Description: - Netupitanto 300 mg, once daily, on chemotherapy day;
Study NCT04669132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonesetron
Description: - Palonosetron 0.56 mg, once daily, on chemotherapy day;
Study NCT00541970 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Intramuscular injection, different dosing /schedule
Study NCT03481907 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nuvagen Collagen Powder
Description: Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
Study NCT00541970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, different dosing /schedule
Study NCT03770858 — intervention group
Intervention type: DRUG
Intervention: Crisaborole
Description: Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
Study NCT02374034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corrective exercise
Description: Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
Study NCT03587818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: person-centred communication
Description: The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
Study NCT02219841 — intervention group
Intervention type: PROCEDURE
Intervention: radiofrequency catheter ablation
Study NCT03770858 — intervention group
Intervention type: DEVICE
Intervention: Scratch sensor
Description: advanced, flexible and wearable skin sensor
Study NCT02777411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
Description: Two vaccinations at 28 days apart
Study NCT00622466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
Study NCT00622466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
Study NCT04852900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decompression with 30%
Description: * Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks
Study NCT04852900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decompression with 40%
Description: * Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks
Study NCT04852900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decompression with 50%
Description: * Hot Pack for 10 mins Soft Tissue Mobilization~* Muscle Strengthening~* Decompression with 30% The total time for the session will be 45 minutes and there will be 03 sessions/week for 6 weeks
Study NCT02777411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)
Description: Two vaccinations at 28 days apart
Study NCT02777411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)
Description: Two vaccinations at 28 days apart
Study NCT02777411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (2 μg total protein per dose)
Description: Two vaccinations at 28 days apart
Study NCT00616941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 OLP4
Description: 1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
Study NCT00616941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 OLP4 + Montanide
Description: 1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
Study NCT00616941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 OLP4 + Montanide + Poly-ICLC
Description: 1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
Study NCT00667810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Study NCT00667810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Study NCT00667810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Study NCT02777411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (1 μg total protein per dose)
Description: Two vaccinations at 28 days apart
Study NCT02901691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: musical rhythmic stimulation
Study NCT02901691 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: musical rhythmic stimulation
Study NCT03269357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: LARC forward structured contraceptive counselling
Description: Training of health care providers (HCPs), use of information material and counselling tools
Study NCT00589797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activ-L Artificial Disc
Description: Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Study NCT00589797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProDisc-L Total Disc Replacement or Charité Artificial Disc
Description: Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Study NCT03084705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manumeter
Description: A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
Study NCT01000506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab 750
Description: Mepolizumab 750mg every four weeks by i.v.
Study NCT01000506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab 250
Description: Mepolizumab 250mg every four weeks by i.v.
Study NCT01000506 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mepolizumab 75
Description: Mepolizumab 75mg every four weeks by i.v.
Study NCT01000506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline
Description: Placebo saline every four weeks by i.v.
Study NCT04312503 — intervention group
Intervention type: DRUG
Intervention: Lurasidone
Description: Patients are treated with dosages according clinical practice
Study NCT04312503 — intervention group
Intervention type: DRUG
Intervention: aripiprazole, olanzapine, quetiapine or risperidone
Description: Patients are treated with dosages according clinical practice
Study NCT01397227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)
Description: Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine in the PCA was given iv.
Study NCT01397227 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)
Description: Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
Study NCT01397227 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
Study NCT02909660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioural therapy
Description: Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
Study NCT02909660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Description: Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
Study NCT01725802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa solution for SC administration
Study NCT01725802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00318240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: Treatment of Radiation failure in Prostate Cancer
Study NCT03521154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib 80mg/40mg
Description: The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
Study NCT03521154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Osimertinib 80mg/40mg
Description: The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met
Study NCT03701646 — intervention group
Intervention type: DEVICE
Intervention: Measurement by Clearsight device
Description: Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
Study NCT03840213 — intervention group
Intervention type: BEHAVIORAL
Intervention: Filling a questionnaire and interviewDescription
Description: The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey.
Study NCT02864264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986184
Study NCT02864264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-986184
Study NCT04173182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Probe-based confocal laser endomicroscopy evaluation
Description: Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
Study NCT00419055 — intervention group
Intervention type: PROCEDURE
Intervention: Early discharge after percutaneous coronary intervenntion
Description: Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
Study NCT03396887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: U Control Drink Smartphone Application
Description: The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
Study NCT03396887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will receive treatment as usual.
Study NCT02957513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Messaging (TM)
Description: As specified in the arm description above
Study NCT02957513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Description: As specified in the arm description above
Study NCT02957513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching (HC)
Description: As specified in the arm description above
Study NCT02957513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching (HC)
Description: As specified in the arm description above
Study NCT02957513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EC)
Description: As specified in the arm description above
Study NCT00745329 — intervention group
Intervention type: OTHER
Intervention: sperm quality test
Description: All participants will undergo sequential sperm quality tests and blood tests
Study NCT02348905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel 40 units twice weekly
Description: ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
Study NCT02348905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTHAR Gel 80 units twice weekly.
Description: ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
Study NCT04719858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #LIFEGOALS
Description: Digital health behaviour change intervention including:~1. self-regulation component with Fitbit: goal setting, monitoring, feedback;~2. narrative component: every week participants receive a new episode (2-5 minutes) of a youth series modeling the target behaviours;~3. chatbot component: automated virtual coach that will send encouraging messages and give an automated answer to user questions.~Participants install the #LIFEGOALS app on their own mobile phone and are asked to use the app during 12 consecutive weeks. Three times per week a notification will be sent to encourage engagement with the intervention.
Study NCT01625104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non Intervention
Description: Business as usual
Study NCT01625104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agressive Intervention Process Improvement Strategies
Study NCT03284567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Football fitness
Description: The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., \< 5°C or heavy rain) training will be performed indoors
Study NCT02646358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepoloxamer
Study NCT02949375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo gel capsule to be taken daily for 28 days
Study NCT02949375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator:4.5mg GRI-0621
Description: 4.5mg GRI-0621 gel capsule to be taken daily for 28 days
Study NCT02949375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: 6.0mg GRI-0621
Description: 6.0mg GRI-0621 gel capsule to be taken daily for 28 days
Study NCT00541268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICD
Description: Intracardioverter defibrillators from 2 different manufacturers
Study NCT02679807 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animalis subsp. lactis Bl-04
Study NCT02679807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Study NCT04235439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gan & Lee Insulin Lispro Injection
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
Study NCT04235439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Lispro Injection
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area by use of a disposable prefilled pen.
Study NCT04383093 — intervention group
Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Combination therapy of daily tadalafil plus tamsulosin
Study NCT03800030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma tACS
Description: NeuroConn technologies, direct current-stimulator plus
Study NCT03800030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS
Description: NeuroConn technologies, direct current-stimulator plus
Study NCT01661868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Tablet formulation will be used.
Study NCT03715959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration of Breast
Description: Undergo NAF
Study NCT03715959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo NAF
Study NCT03361072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy
Description: Milk, peanut or egg oral immunotherapy
Study NCT00436293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m²
Study NCT00436293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m²
Study NCT01902862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m\^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
Study NCT01902862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as intravenous infusion as 375 mg pert m\^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
Study NCT01989182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiration Valve System
Study NCT01989182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Study NCT03800030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tACS
Description: NeuroConn technologies, direct current-stimulator plus
Study NCT04595643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of different dysphagia training modalities
Description: Neuromuscular electrical stimulation, Masako exercises, Mendelsohn maneuver, chin down, mobilization, shaker exercises, eating different food consistencies.
Study NCT01989182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Study NCT05232656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Discharge Checklist and Patient Safety Dashboard
Description: Pre-discharge preparation checklist for patients to assess discharge readiness. Patient safety dashboard for clinicians to proactively identify at-risk patients.
Study NCT02569346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Single-dose Triumeq as a whole tablet
Study NCT02569346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq crushed + breakfast
Description: Single-dose crushed and suspended tablet of Triumeq
Study NCT02569346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triumeq crushed + breakfast
Description: Single-dose crushed and suspended tablet of Triumeq